NO EFFECT OF INSULIN-TREATMENT OR GLYCEMIC IMPROVEMENT ON PLASMA CARNITINE LEVELS IN TYPE-2 DIABETIC-PATIENTS

被引：0
|
作者：
PREGANT, P
KAISER, E
SCHERNTHANER, G
机构：
[1] KRANKENANSTALT RUDOLFSTIFTUNG WIEN,MED 1 ABT,JUCHGASSE 25,A-1030 VIENNA,AUSTRIA
[2] UNIV VIENNA,INST MED CHEM,A-1010 VIENNA,AUSTRIA
来源：
CLINICAL INVESTIGATOR | 1993年 / 71卷 / 08期
关键词：
CARNITINE; TYPE-2; DIABETES-MELLITUS; METABOLIC INTERVENTION;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Carnitine is an essential factor for the transport of long-chain fatty acids and is important for the heart muscle. A longitudinal study in type 2 diabetic patients was carried out. Carnitine levels were observed before and during metabolic intervention with dietary measures and either sulfonylurea or insulin treatment. In both treatment groups a significant glycemic improvement was observed after 3 months (insulin treatment group: hemoglobin A1c 11.3 +/- 2.8 versus 7.0 +/- 1.0; sulfonylurea treatment group; hemoglobin A1c 11.3 +/- 1.4 versus 7.3 +/- 0.9). Carnitine levels did not differ from a control group and did not change significantly during the observed period.
引用
收藏
页码：610 / 612
页数：3
相关论文
共 50 条
  • [1] NATRIURETIC AND VASOACTIVE HORMONES AND GLOMERULAR HYPERFILTRATION IN HYPERGLYCEMIC TYPE-2 DIABETIC-PATIENTS - EFFECT OF INSULIN-TREATMENT
    LALAU, JD
    WESTEEL, PF
    TENENBAUM, F
    DEBUSSCHE, X
    NUSSBERGER, J
    TRIBOUT, B
    FARDELONNE, P
    FAVRE, H
    FOURNIER, A
    NEPHRON, 1993, 63 (03): : 296 - 302
  • [2] HEMOSTATIC ABNORMALITIES PERSIST DESPITE GLYCEMIC IMPROVEMENT BY INSULIN THERAPY IN LEAN TYPE-2 DIABETIC-PATIENTS
    KNOBL, P
    SCHERNTHANER, G
    SCHNACK, C
    PIETSCHMANN, P
    PROIDL, S
    PRAGER, R
    VUKOVICH, T
    THROMBOSIS AND HAEMOSTASIS, 1994, 71 (06) : 692 - 697
  • [3] COMPARISON BETWEEN ACARBOSE, METFORMIN, AND INSULIN-TREATMENT IN TYPE-2 DIABETIC-PATIENTS WITH SECONDARY FAILURE TO SULFONYLUREA TREATMENT
    CALLEPASCUAL, AL
    GARCIAHONDUVILLA, J
    MARTINALVAREZ, PJ
    VARA, E
    CALLE, JR
    MUNGUIRA, ME
    MARANES, JP
    DIABETES & METABOLISM, 1995, 21 (04) : 256 - 260
  • [4] THE EFFECT OF ETOMOXIR ON INSULIN SENSITIVITY IN TYPE-2 DIABETIC-PATIENTS
    HUBINGER, A
    WEIKERT, G
    WOLF, HPO
    GRIES, FA
    HORMONE AND METABOLIC RESEARCH, 1992, 24 (03) : 115 - 118
  • [5] PLASMA-LIPID LEVELS AT DIAGNOSIS IN TYPE-2 DIABETIC-PATIENTS
    SOSENKO, JM
    KATO, M
    SOTO, R
    GOLDBERG, RB
    DIABETIC MEDICINE, 1993, 10 (09) : 814 - 819
  • [6] SUPPRESSION BY INSULIN-TREATMENT OF THE GLUCOSE-INDUCED PARADOXICAL INHIBITION OF INSULIN RELEASE IN TYPE-2 (NON-INSULIN-DEPENDENT) DIABETIC-PATIENTS
    NOVIALS, A
    GOMIS, R
    COVES, MJ
    FERRER, J
    CASAMITJANA, R
    MALAISSE, WJ
    DIABETOLOGIA, 1989, 32 (07) : A523 - A523
  • [7] DISAPPEARANCE RATE OF INSULIN-ANTIBODIES AFTER DISCONTINUING INSULIN-TREATMENT IN 42 TYPE-2 (NON-INSULIN-DEPENDENT) DIABETIC-PATIENTS
    IONESCUTIRGOVISTE, C
    MINCU, I
    SIMIONESCU, L
    CHETA, D
    MIRODON, Z
    SANTU, E
    POPA, E
    BIRNEA, A
    DIABETOLOGIA, 1984, 27 (06) : 592 - 595
  • [8] ADVANTAGES OF INTENSIVE CONTINUOUS SUBCUTANEOUS INSULIN-TREATMENT OF SHORT DURATION IN VERY POORLY CONTROLLED OVERWEIGHT TYPE-2 DIABETIC-PATIENTS
    MOURA, I
    ATTALI, JR
    VALENSI, P
    SEBAOUN, J
    DIABETES & METABOLISM, 1987, 13 (04): : 483 - 483
  • [9] LIPOPROTEIN(A), APOLIPOPROTEIN(A) POLYMORPHISM, AND INSULIN-TREATMENT IN TYPE-II DIABETIC-PATIENTS
    BUSCAGLIA, P
    GAZZARUSO, C
    GARZANITI, A
    BONETTI, G
    FRATINO, P
    GEROLDI, D
    DIABETES CARE, 1995, 18 (08) : 1202 - 1203
  • [10] IMPROVEMENT OF POSTRECEPTOR INSULIN DEFECT IN TYPE-2 (NON-INSULIN-DEPENDENT) DIABETIC-PATIENTS BY METFORMIN
    TIENGO, A
    DELPRATO, S
    PADOVAN, D
    NOSADINI, R
    DUNER, E
    MARESCOTTI, C
    AVOGARO, A
    TREVISAN, R
    DEKREUTZENBERG, SV
    DIABETOLOGIA, 1982, 23 (02) : 205 - 205
12345